Fiscal 2024 Guidance
Fiscal 2024 Guidance | ||
| Revenue | $69M - $72M | |
| Revenue growth | 15 - 20% | |
| Software mix | 55 - 60% | |
| Services mix | 40 - 45% | |
| Diluted EPS | $0.46 - $0.48 | |
| Adjusted diluted EPS | $0.54 - $0.56 |
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2025 | Buy → Neutral | BTIG Research | |
| 9/30/2025 | $16.00 | Hold | TD Cowen |
| 7/15/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/15/2024 | $39.00 | Overweight | Stephens |
| 7/29/2024 | $47.00 | Overweight | KeyBanc Capital Markets |
| 7/16/2024 | Mkt Perform | JMP Securities | |
| 6/28/2024 | Outperform | William Blair | |
| 5/9/2023 | $55.00 | Buy | BTIG Research |
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
DEFA14A - Simulations Plus, Inc. (0001023459) (Filer)
SCHEDULE 13G - Simulations Plus, Inc. (0001023459) (Subject)
Expert panel at the 2026 ASCPT Annual Meeting brings together leaders with industry and regulatory experience to explore practical, accountable AI implementation Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a high-impact panel discussion, "From Debate to Deployment: Responsible, Practical AI in MIDD," to be held during the upcoming American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting on March 5, 2026 at 12:00 PM MST in Denver, CO. "There is no longer a question of whether artificial intelligence (AI) should be
Extended projects support ongoing research into computational approaches and new approach methodologies for food and chemical safety assessment Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced the extension of two separate research collaborations with the U.S. Food and Drug Administration (FDA) and the National Institute of Environmental Health Sciences (NIEHS). The extended projects support ongoing federal research efforts focused on the development of new approach methodologies (NAMs) and advancing computational approaches for food and chemi
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the upcoming investor conferences: BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Format: One-on-one meetings When: Tuesday, February 10, 2026 Location: Snowbird, Utah TD Cowen 46th Annual Health Care Conference Format: Fireside chat and one-on-one meetings When: Tuesday, March 3, 2026 Location: Boston, Massachusetts KeyBanc Healthcare Forum Format: Fireside chat and one-on-one meetings When: W
BTIG Research downgraded Simulations Plus from Buy to Neutral
TD Cowen initiated coverage of Simulations Plus with a rating of Hold and set a new price target of $16.00
KeyBanc Capital Markets downgraded Simulations Plus from Overweight to Sector Weight
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 22, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Uber Technologies Inc. (NYSE:UBER) will replace Charter Communications Inc. (NASD: CHTR) in the S&P 100. Charter Communications will remain in the S&P 500.AppLovin Corp. (NASD: APP), Robinhood Markets Inc. (NASD: H
QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among
Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025. First Quarter 2026 Financial Highlights (as compared to first quarter 2025) Total revenue decreased 3% to $18.4 million Software revenue decreased 17% to $8.9 million, representing 48% of total revenue Services revenue increased 16% to $9.5 million, representing 52% of total revenue Gross profit was $10.9 million and gross mar
Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 201-389-0879 (in
Reaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software revenue decreased 9% to $9.0 million, representi